Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
about
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanomaFc glycans of therapeutic antibodies as critical quality attributesA perspective on the structure and receptor binding properties of immunoglobulin G FcLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsIn vitro and in vivo modifications of recombinant and human IgG antibodiesProtein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profilesChemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan BiosynthesisSelective Deactivation of Serum IgG: A General Strategy for the Enhancement of Monoclonal Antibody Receptor InteractionsEngineering Hydrophobic Protein–Carbohydrate Interactions to Fine-Tune Monoclonal AntibodiesImmunoglobulin G1 Fc Domain Motions: Implications for Fc EngineeringCrystal structure of deglycosylated human IgG4-FcImmune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesFc gamma receptors: glycobiology and therapeutic prospectsA testis-specific regulator of complex and hybrid N-glycan synthesis.Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.Influence of glycosylation pattern on the molecular properties of monoclonal antibodies.High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans.Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCCTwo mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects.Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties.Molecular cloning, characterization, genomic organization and promoter analysis of the α1,6-fucosyltransferase gene (fut8) expressed in the rat hybridoma cell line YB2/0Alterations in glycopeptides associated with herceptin treatment of human breast carcinoma mcf-7 and T-lymphoblastoid cellsAnalysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2007-2008.SweetBac: a new approach for the production of mammalianised glycoproteins in insect cells.Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeuticsGlycosylation profiling of therapeutic antibodies in serum samples using a microfluidic CD platform and MALDI-MS.High-throughput glycosylation analysis of therapeutic immunoglobulin G by capillary gel electrophoresis using a DNA analyzerTreatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin GChemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor.Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans.Increased serum clearance of oligomannose species present on a human IgG1 molecule.The impact of microcarrier culture optimization on the glycosylation profile of a monoclonal antibody.Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation.The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation
P2860
Q24629841-CE01E3DB-6C27-47D3-84F1-5778ECA90997Q26799266-67096345-2298-4239-890F-9C9D9CAB58F1Q26827579-C1B4F7E3-F345-4AEA-8BED-41F3E7844DB1Q26849243-1F0704E5-AFDC-4ACC-A487-49CA24A18FCEQ26859713-D38DE6A3-F44D-4C09-9EF1-94B93F518F80Q26998787-2FC246B2-8F00-43CF-890E-199178885E00Q27673777-3DD38070-C421-476B-B7BA-9B9C5BC8C4B7Q27678384-51205CD7-A71D-470C-BF1E-23BDE70CEA4EQ27678524-D5D87650-029A-40EF-874D-CBE3EED441E5Q27681704-1AE4ABBB-4FA1-4EB8-9A01-4293F2026B42Q27684440-DB34E206-BBFC-461D-8329-91ACA2BA05DAQ28069362-1AF3B15E-6219-4AC9-9EEB-0938FFAE8656Q28076303-544B0987-0FF3-49C2-8156-B1956FAC6BA3Q29347272-4C180367-CFFF-44CF-9BF3-7A6F51A61E97Q30224854-50D07945-D720-448D-83B5-A4C91B3E9BDCQ30360566-C5431C56-34B9-4D9B-8699-E8371DE3620CQ30675226-21495A6F-8154-45BE-9B65-64BADB578B8EQ31004131-E7C87FB1-0727-4372-8790-C0694D485A0BQ33307815-655B6349-8623-4E56-B730-1B6F70C21473Q33410392-A2D2EF82-59A5-40C2-B5DF-BA30516EB7C7Q33420988-458CD9B2-8312-4EDC-ADCA-09FEDAEFED91Q33551688-F7A9DF4C-2EF2-485E-B6BF-4E87A59ED7F2Q33786180-BD962348-E873-4B60-AD93-9182AD9E68D3Q33910762-6D443C0A-71EA-4039-88C9-89B5FC506BD8Q33995843-C548840E-2748-4B44-9F9F-B672679C8A88Q34224840-D346764C-2ABE-477A-AD9C-32801BD36133Q34275537-3D97F7BE-D874-4E73-8934-9C1B3CFC91D6Q34697409-0551EE12-3FF1-4505-A355-D49EA8856415Q35019925-CE24F45C-D242-4AEF-ACF8-77A96B4D5D7CQ35063963-1A19E98E-BA97-4B9E-95BF-AE84CF115248Q35555990-1A44A073-1683-4B14-998D-6AF236DF9E7CQ35705039-B225807D-22C2-4509-93CD-556AD3FFE792Q35866472-2BF84EDD-C28A-4B07-BC59-153946A33E0AQ36131665-CA622671-4A4A-45EF-96A2-A3910E2AF2BCQ36213158-6EC268A8-9DB0-43E4-8E21-69300AEEC327Q36402805-EAF63913-463F-469A-8617-FF7CE90C4EC2Q36402812-ACF19CFE-5BEC-49CC-B556-7D66A7C3C30BQ36670313-E7F11EE3-95D6-4A28-B381-FE0A042E793AQ37066000-1579E9CF-B4BD-485C-B6F2-D3DD427C62B8Q37090829-431939EB-98EB-4279-8808-0EF3D802EAA6
P2860
Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Comparison of biological activ ...... se, hybrid, and complex types.
@en
type
label
Comparison of biological activ ...... se, hybrid, and complex types.
@en
prefLabel
Comparison of biological activ ...... se, hybrid, and complex types.
@en
P2093
P2860
P356
P1433
P1476
Comparison of biological activ ...... se, hybrid, and complex types.
@en
P2093
Akira Okazaki
Katsuhiro Mori
Kazuko Kitajima-Miyama
Keiichi Yano
Kenya Shitara
Miho Inoue
Mitsuo Satoh
Reiko Kuni-Kamochi
Ryosuke Nakano
Shingo Kakita
P2860
P304
P356
10.1093/GLYCOB/CWL057
P577
2006-09-29T00:00:00Z